• 1
    IARC. IARC handbooks of cancer prevention: cervix cancer screening, vol. 10. Lyon: IARC Press, 2005. 302.
  • 2
    Lönnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 2012; 23: 17280.
  • 3
    Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. Br Med J 2009; 339: b2968.
  • 4
    Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, Dillner J, Törnberg S. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100: 6229.
  • 5
    Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomized evaluation trial. BMC Public Health 2006; 6: 252.
  • 6
    Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A. Age-specific evaluation of primary human papillomavirus screening vs. conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 161223.
  • 7
    van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008; 122: 18548.
  • 8
    Anttila A, Nieminen P. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. Coll Antropol 2007; 31 (Suppl 2): 1722.
  • 9
    Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S, Sparen P. Screening and cervical cancer cure: population based cohort study. Br Med J 2012; 344: e900.
  • 10
    Duffy SW, Cuzick J, Tabar L, Vitak B, Chen TH-H, Yen M-F, Smith RA. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. J R Stat Soc Ser C 2002; 51: 23543.
  • 11
    Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer 2003; 89: 8893.
  • 12
    Engholm G, Ferlay J, Christensen N, Johannesen TB, Klint Å, Køtlum JE, Milter MC, Ólafsdóttir E, Pukkala E, Storm HH. NORDCAN: cancer incidence, mortality, prevalence and survival in the nordic countries, Version 5.1 (March 2012): association of the nordic cancer registries. Danish Cancer Society.
  • 13
    Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 2004; 90: 17846.
  • 14
    Sasieni P, Castanon A, Cuzick J. Screening and adenocarcinoma of the cervix. Int J Cancer 2009; 125: 5259.
  • 15
    Weiss NS. Case-control studies of the efficacy of screening tests designed to prevent the incidence of cancer. Am J Epidemiol 1999; 149: 14.
  • 16
    Terveyden ja hyvinvoinnin laitos. Terveyden ja hyvinvoinnin laitoksen asettaman papilloomavirustautien torjuntatyöryhmän selvitys [Report of the study by the Expert Group on Papillomavirus Disease Prevention appointed by the National Institute for Health and Welfare]. Available at:
  • 17
    Nieminen P, Kallio M, Anttila A, Hakama M. Organized vs. spontaneous Pap-smear screening for cervical cancer: a case-control study. Int J Cancer 1999; 83: 558.